Please assess the completion status of the following clinical trial:

Trial Title: A Comparative Study of Artekin With Standard Malarial Treatment Regimes in Afghanistan

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Uncomplicated falciparum or vivax malaria or mixed species infection, as confirmed in a peripheral blood slide.~* No signs of severe malaria~* Age over three months.~* Non-pregnant, (test for β-HCG in women of child-bearing age).~* Weight ≥5 kg~* Willingness to participate and written informed consent provided by the patient or in case of children by attending guardians/parents.~* Not enrolled in any other investigational drug study in the previous month~Exclusion Criteria:~* Clinical or laboratory features suggesting severe malaria.~* Known cardiac, renal, hepatic or other severe disease, or requirement for hospital treatment~* Recurrent vomiting.~* Not eligible for follow-up.~* Lactating mother~* Hyperparasitemia of P. falciparum \> 100,000/µL~* Treatment with Artesunate or Chloroquine in the past one month, Fansidar in the past one and the half months and Artekin in past 3 months.

- Gender: ALL
- Minimum Age: 3 Months
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Artekin (Type: EXPERIMENTAL): Dihydroartemisinin+ Paperaquine (DHA+PPQ, Artekin)
- Standard treatment (Type: ACTIVE_COMPARATOR): The standard treatment for uncomplicated falciparum and vivax malaria are as follows:~Uncomplicated falciparum: artesunate-sulphadoxin/pyrimethamine Vivax malaria: chloroquine

Based on this trial design, predict the completion outcome and termination type (if applicable).